To The Moon

Eli Lilly executive Jacob Van Naarden has indicated that the company, bolstered by the substantial cash flow from GLP-1 weight-loss drugs like Mounjaro and Zepbound, is implementing a new mergers and acquisitions strategy.

Van Naarden holds a dual role, leading the oncology business unit while also recently taking on the position of head of corporate development.

The company's M&A spending so far this year has already surpassed its total acquisition outlay for the entire previous year.

Jacob Van Naarden currently has a full plate. In addition to overseeing Eli Lilly's oncology operations, he now also serves as the head of corporate development, tasked with identifying acquisition opportunities for the pharmaceutical giant. As Eli Lilly ascends to the top of the global pharmaceutical industry, its appetite for expansion through acquisitions is at a historical peak.

In an interview at the American Society of Clinical Oncology annual meeting, Van Naarden stated, "Thanks to the strong revenue from the weight-loss drug segment, the company's financial foundation is currently very solid. We are presented with a generational opportunity for capital reallocation, allowing us to deploy funds across all disease areas. This will both support the company's growth for decades to come and help vast numbers of patients with various conditions. The company is steadily implementing its investment strategy around this goal."

With the year not yet half over, Eli Lilly has already announced eight acquisition deals, with initial upfront payments exceeding $10 billion and potential total expenditures reaching up to $25 billion. In contrast, the company completed about 40 transactions for the entirety of last year, with a combined M&A spend of only $4 billion.

This surge in spending marks a strategic shift in Eli Lilly's acquisition approach. The company's size and valuation are now at record highs. According to London Stock Exchange Group data, Eli Lilly's current market capitalization is approximately $1 trillion, a significant increase from $190 billion in 2021. It is the first pharmaceutical company to join the trillion-dollar market cap club, a group previously dominated by technology firms.

Historically, Eli Lilly favored making low-cost bets on high-risk, early-stage clinical pipelines. Now, with the substantial profits generated by the GLP-1 weight-loss drugs Mounjaro and Zepbound, the company is shifting towards higher-priced acquisitions of mid-to-late-stage drug candidates with a higher probability of clinical success.

In another interview at his office in Stamford, Connecticut, Van Naarden explained, "Uncertainties in drug development projects are an objective reality; final sales volume, development pathways, and approval timelines cannot be precisely predetermined in advance. While we conduct financial assessments, as long as a project's clinical value is solid, we are willing to pay a price far exceeding that for early-stage, pre-clinical projects. At this stage, while maintaining a large portfolio of early-stage projects, we are significantly shifting our focus towards acquiring high-quality mid-to-late-stage assets."

Van Naarden revealed that last fall, Eli Lilly CEO Dave Ricks asked him to take on the additional role of head of corporate development alongside his existing oncology responsibilities. The company aims to strengthen its M&A capabilities and move beyond its previous investment focus limited to early-stage startup projects.

This related M&A strategy has been formally implemented since the beginning of this year.

In March, the company announced the acquisition of Senti Biosciences. If the latter's sleep disorder drug candidates, such as for narcolepsy, achieve certain development milestones, the total deal value could reach up to $7.8 billion, making it Eli Lilly's second-largest acquisition ever, second only to the $8 billion acquisition of Loxo Oncology in 2019 (where Van Naarden previously served as COO).

While an $8 billion deal is significant for Eli Lilly, it remains a mid-sized transaction compared to other global pharmaceutical leaders, leading to market curiosity about the company's future acquisition ceiling.

Van Naarden declined to set a rigid monetary cap for acquisitions, stating that whether to proceed with a deal depends solely on the project's scientific value, clinical value for patients, and commercial potential.

Some of this year's acquisitions focus on Eli Lilly's traditional four core therapeutic areas: oncology, neuroscience, cardio-metabolic diseases, and immunology. Several other deals, however, expand beyond the existing portfolio, such as the recent consecutive acquisitions of three vaccine companies, officially entering the new field of vaccines.

Van Naarden stated at the ASCO meeting, "We are looking at numerous areas outside our four main business categories. It should not be surprising if more cross-industry acquisitions follow. Once we decide to acquire, it means we are optimistic about the project's prospects and confident it can create significant industry value."

When asked if there were any acquisition directions Eli Lilly would absolutely avoid, he responded plainly, "There are essentially no forbidden zones."